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I. NEED FOR RELENTLESS INNOVATION
THROUGH R&D
The need to innovate in this rapidly changing economy to
create new and higher value is given. At the Agency for
Science, Technology and Research ASTAR, innovation is
our raison d’etre to help create the future of Singapore.
Data Storage Institute DSI is one of ASTAR’s research
institutes RIs. It was established to support the growth of
the data storage industry in Singapore. In the early days of
DSI in the 1990s, one in two disk-drives worldwide was
made in Singapore. Over time, the production of such disk-
drives began to move to lower cost countries. DSI continued
to develop new capabilities and innovate and supported the
shift of the data storage industries toward higher value-added
activities.
Today, eight out of ten higher value-added high-end en-
terprise drives and nearly ﬁve out of ten hard disk media are
manufactured in Singapore. These growth and success of the
data storage industry in Singapore have also persuaded key
industry players, such as Seagate, Fujitsu, EMC, Seiko, and
Nitto Denko, to establish corporate R&D laboratories in Sin-
gapore. Seiko and Nitto Denko, in particular, are now colo-
cated with DSI in Fusionopolis—the science and engineering
hub in Singapore. We are mindful that these companies will
remain in Singapore for as long as we continue to offer a
competitive value proposition.
This is why DSI has to continue to look ahead to build
capabilities to support the key industry players on develop-
ing next-generation products such as cost-competitive non-
volatile memory devices and high density magnetic storage
at 10 Tbytes / in.2.
The challenge therefore is how to do this right by lever-
aging on what little natural or man-made advantages that
Singapore has to sustain Singapore’s competitive advantage.
This is the only way for us to achieve our mission to foster
world-class research and talent for Singapore in this
knowledge-based and innovation-driven world, and it is how
we can contribute toward establishing Singapore as Asia’s
innovation capital.
II. CAPITALIZING ON THE NATURAL ADVANTAGES
OF OUR ENVIRONMENT
There are inherent strengths in Singapore that we can
capitalize on to innovate so as to achieve our mission. The
Massachusetts Biotechnology Council’s April 2009 report on
“Strategic Outlook for 2015 and Strategic Plan,” noted that
Singapore, an emerging biotech cluster, was “aiming to
move up the value chain and position itself as a world-class
center for R&D through signiﬁcant government investment.”
It noted that Singapore’s key strengths lie in the following:
1 supportive government committed to R&D,
2 integrated and well-connected public sector,
3 educated and skilled workforce, and
4 supportive business and regulatory environment.
These strengths enable ASTAR to adopt certain differen-
tiating strategies at various stages of our development to
achieve our mission. Some of these strategies include the
following:
1 creating the biomedical sciences hub in Biopolis to
jump-start the development of biomedical sciences
BMS R&D efforts,
2 establishing the science and engineering hub in Fusion-
opolis in close proximity to Biopolis to spearhead mul-
tidisciplinary and cross council research in ASTAR,
3 collaborating with industry in R&D through responsive
innovation platforms,
4 partnering clinicians in hospitals for bench to bedside
translational work and biomedical engineering innova-
tion, and
5 enthusing and providing young people with many oppor-
tunities to pursue the study of science and a career in
R&D.
III. CREATING THE BMS HUB IN BIOPOLIS AND
JUMP-STARTING BMS R&D
A. The BMS initiative
Since its inception in 2002, ASTAR has been the engine
that powers the BMS R&D. BMS was then identiﬁed as a
new growth area in Singapore. Once a strategic decision was
taken to proceed, ASTAR quickly set out to create the BMS
cluster and build Biopolis from scratch to be a BMS hub of
the world.
In the ﬁrst phase of the BMS initiative 2000–2005, key
building blocks were put in place to establish core scientiﬁc
BMS research capabilities through the development of hu-
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man capital, intellectual capital, and industrial capital. In the
second phase of the initiative 2006–2010, the focus was on
strengthening basic research while building new capabilities
in translational and clinical research. This allows scientiﬁc
discoveries from the bench to be translated to the bedside to
improve human health and healthcare delivery, and ulti-
mately contribute to the economy and bring beneﬁts to soci-
ety.
B. Attracting and developing human capital
ASTAR’s undergirding strategy in R&D is talent. We
recognize early that knowledge creation and value-
generating R&D activities go where there are world-class
research talent and technological expertise. With a limited
population base of only 5106 in Singapore, there is a
pressing need to devise a holistic talent strategy to attract and
develop world-class scientists, both local and international,
at all levels and areas in its R&D landscape.
Internationally renowned scientists were attracted to come
to ASTAR to pursue their passion in science, and help Sin-
gapore develop new capabilities and create new knowledge.
They include top scientists such as Edward Holmes and Ju-
dith Swain from University of California, San Diego, Edison
Liu, Neal Copeland and Nancy Jenkins from National Can-
cer Institute, David and Birgit Lane from the University of
Dundeee, UK, as well as Jackie Ying from MIT. They helped
to jumpstart Singapore’s BMS efforts, provide leadership to
the RIs under ASTAR and mentor young scientists in the
RIs.
To ensure that we have a strong pipeline of young talent
to support the growing BMS research and manufacturing ac-
tivities, ASTAR also provides a slew of scholarships for the
most capable and committed young Singaporeans to pursue
undergraduate and graduate scientiﬁc training in top univer-
sities locally and around the world. Many of our scholars and
fellows can be found in top U.S. and UK universities. Ac-
cording to Stanford University president, Professor John
Hennessy, Singapore has the highest per capita Ph.D. stu-
dents in Stanford with almost all of them on ASTAR’s
scholarships. In addition, ASTAR also offers many oppor-
tunities for top international students to pursue all or part of
their research training in Singapore.
C. Building intellectual and industrial capital
Today, ASTAR’s biomedical medical research council
BMRC has seven RIs and ﬁve research consortia under its
umbrella. We have also built up considerable strengths in six
key research areas spanning the whole spectrum of BMS
research from basic to translational and clinical research. The
research areas include biomedical engineering and biopro-
cessing; cancer genetics; infectious disease and immunology;
metabolic diseases; molecular, cell, and development biol-
ogy; and stem cells and regenerative medicine. These are
well supported by platform technologies such as bioimaging;
bioinformatics and genomic sequencing capabilities. Taken
together, they are aligned with four main industry sectors—
biotechnology and biologics, healthcare services and deliv-
ery, medical engineering and technology, and pharmaceuti-
cals.
The BMRC research institutes and research consortia are
housed in Biopolis, the BMS hub. Biopolis has grown into
an integrated R&D complex with more than 2106 ft2 of
space. It also houses corporate laboratories of international
and local pharmaceutical and biotechnology companies. This
colocation of private and public sector research is a unique
feature of Biopolis. It enables scientists from ASTAR and
industry to exchange ideas and explore collaborations, thus
facilitating the commercialization of our research outputs. It
also enables private sector laboratories to make use of shared
infrastructure, such as research equipment, core scientiﬁc
services, and conference facilities that also support the public
sector institutes. Together with the many residential, recre-
ational, and entertainment options in the immediate vicinity,
Biopolis is an excellent plug-and-play location for industry
R&D with access to world-class scientiﬁc collaborators
within the ASTAR RIs.
D. Success of BMS R&D and Biopolis
Singapore’s BMS R&D efforts have elicited positive at-
tention internationally. In May 2007, Massachusetts gover-
nor, Deval Patrick, was quoted by Boston Globe as saying
that Singapore was one of the top “competitor states and
foreign nations” to Massachusetts’ life sciences initiative
when he announced his $1 billion life sciences initiative at
BIO International Convention 2007. The same report noted
that the administration felt that one of the top “challenges”
for Massachusetts’ initiative was that “the United Kingdom,
Ireland, China, and Singapore had developed coordinated
strategies to attract researchers and companies.” Across the
Atlantic in the United Kingdom, Lord Martin Rees, the
President of the Royal Society, and the Master of Trinity
College in Cambridge, was quoted in an article by the Press
Association in December 2008 as comparing Biopolis favor-
ably with the UK Center for Medical Research and Innova-
tion UK CMRI. He said that just as Biopolis in Singapore
had sent a signal, the creation of the UK CMRI would send
a signal from London to raise the standing of science.
In terms of private sector BMS R&D, Singapore has fared
well. Today, more than 100 global biomedical sciences com-
panies are carrying out strategic business operations ranging
from regional headquarters to cutting-edge research and
manufacturing in Singapore. These include companies such
as Abbott, Roche, GlaxoSmithKline, Merck, Novartis, Pﬁzer,
Schering-Plough, Wyeth, Siemens, and Becton-Dickson. In
terms of economic outcomes, the manufacturing output for
BMS of S$21 billion in 2009 was more than a threefold
increase from the S$6.3 billion in 2000. BMS’s share of
Singapore’s total manufacturing output had also increased
from 3.9% in 2000 to 10% in 2009. The compound annual
growth rate CAGR from year 2000 to 2009 was 14%—a
good indication of Singapore’s strong and steady progress in
FA4 Lim Chuan Poh: Advancing innovation through R&D the ASTAR way FA4
Biointerphases, Vol. 5, No. 3, September 2010
building up its BMS R&D capabilities. There were also
slightly more than double the jobs in this sector by 2008, up
from less than 6000 jobs in 2000.
Biologics manufacturing is a prime example of how Sin-
gapore’s efforts to build up BMS R&D capabilities have suc-
cessfully attracted large-scale industry investments. The ef-
forts by ASTAR’s Bioprocessing Technology Institute
BTI to develop its bioprocessing capabilities as well as
skilled talent in the ﬁeld attracted leading biologics manufac-
turing multinational corporations MNCs, such as Glaxo-
SmithKline, Baxtor, Roche, and Lonza, to set up
commercial-scale biologics manufacturing plants in Sin-
gapore, which will potentially employ 1300 staff and bring in
more than S$2.5 billion in investments. Building upon this
success, ASTAR’s Singapore Stem Cell Consortium and
BTI engaged Lonza in further discussions which culminated
in the recent establishment of a the Cell Therapy Manufac-
turing Facility in Singapore, the ﬁrst one set up by Lonza
outside the U.S. and Europe. This facility will support and
catalyze the growth of stem cell therapies in the Asia-Paciﬁc
region.
Some signiﬁcant breakthroughs have also been made in
the laboratories with signiﬁcant impact on society. In 2007, a
team of researchers from the Institute of Bioengineering and
Nanotechnology developed the microﬂuidic device and
chemical kit that is capable of detecting the Inﬂuenza A
H5N1 virus using a simple swab sample from the throat.
During the outbreak of the Inﬂuenza A H1N1 virus, the
device was adapted to detect the Inﬂuenza A H1N1 virus
within 2 h when it used to take days. With its unique ability
to perform automated and speedy gene extraction and gene
detection on a wide variety of biological samples including
tissues and body ﬂuids, this technology is now further devel-
oped for the fast and accurate detection of cancer and other
infectious diseases. It is now licensed by SG Molecular Di-
agnostics, a local company. Besides this microﬂuidic device,
ASTAR has also commercialized other technologies, result-
ing in spin-off companies such as VeriStem, Curiox Biosys-
tems, and MerLion Pharmaceuticals.
IV. ESTABLISHING FUSIONOPOLIS AND
VENTURING INTO CROSS COUNCIL RESEARCH
BMRC’s counterpart, Science and Engineering Research
Council SERC, has a longer history in R&D with some
institutes such as Data Storage Institute and Institute of Mi-
croelectronics having their roots in the 1990s. Currently, it
has seven research institutes and one center. The SERC RIs
have built up strengths in eight key areas, namely, biotech-
nology, chemistry, computational and device technologies,
information, communications and media, materials, manu-
facturing technology, mechatronics and automation, and me-
trology. Their research areas are also aligned with four main
industry sectors, namely, electronics, infocomm, chemicals,
and engineering.
Combined, BMRC and SERC have a spectrum of deep
capabilities between them that make it possible for them to
vastly open up the space for research and innovation through
multidisciplinary and cross council collaborations. Such an
approach to research is particularly critical in an age where
problems are so complex that they need solutions that lie not
in a single discipline, but in interfaces between disciplines
and from multiple sources. This concept is well accepted and
actively pursued by top research universities and centers
with varying degrees of success.
Opening of Fusionopolis
ASTAR has a slight edge in this area of engendering
multidisciplinary research by turning a natural constraint of
lack of geographical size into an advantage of collocating
research institutions. In 2008, ASTAR opened
Fusionopolis1 as the science and engineering hub with the
intention of bringing together the diverse capabilities of the
SERC RIs in a compact location. Fusionopolis, which will
also be home to public sector agencies and the private sector
companies, is an emblem of community, collaboration, and
cooperation. It is designed to facilitate the coming together
of talent from different scientiﬁc disciplines and sectors, and
create opportunities for them to contribute their capabilities
as a vibrant and collaborative community.
This physical proximity of Fusionopolis to Biopolis, only
600 m apart, is the natural advantage for ASTAR to drive
cross council research both in an organic manner and at the
organizational level. Opportunities are therefore available for
researchers from either council to meet serendipitously.
These encounters may help to engender conversations which
may spawn new ideas and lead to research collaborations
further down the road. To further facilitate dialog between
researchers from BMRC and SERC, and foster multidisci-
plinary and cross council research, ASTAR set up the
ASTAR Joint Council in 2009. The joint council organizes
meetings and scientiﬁc conferences to bring researchers from
the two councils together to share their various research
projects with one another, as well as provided platforms and
funding for supporting cross council research. This is in-
tended to be catalytic to foster a collaborative environment
within the research community.
Although cross council research at ASTAR is in its na-
scent stage, it is heartening that we are taking small, but
meaningful steps toward such collaborative research. We are
beginning to see some successes in the work-in-progress,
e.g., the research on a home-based medical diagnosis system
or the intelligent toilet bowl. This project brings together
researchers from disparate scientiﬁc disciplines, such as in-
focomm and materials science from SERC, and molecular
and cell biology from BMRC, to research on how to detect
and make a quick and accurate diagnosis of certain illness
and diseases from the qualitative analysis of certain biomar-
kers in a urine sample. This collaborative effort aims to make
healthcare delivery more accessible to people in the future.
Another example is the development of the fastest and least
1Fusionopolis currently houses two of SERC’s RIs. By 2014, all of SERC’s
RIs, with the exception of the Institute of Chemical and Engineering Sci-
ences will be colocated together in Fusionopolis.
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expensive DNA sequencing device based on pyrosequencing
chemistry and high resolution image sensing. This project
brings together the vastly different expertise of DNA se-
quencing from BMRC, and image sensor development and
microﬂuidics from SERC.
One area of research that will beneﬁt greatly from cross
council research is biointerphase science research since it
requires the knowledge and expertise of researchers from a
diverse range of disciplines such as biology, physics, chem-
istry, and materials science. With the space and platforms
readily available for researchers to explore cross council re-
search, it only follows that new knowledge will be created,
innovative scientiﬁc advances made and ingenious technolo-
gies developed to deal with the many challenges prevalent
today and in the future.
ASTAR’s ability to affect cross council research is what
many research hubs have hoped to do but have not yet
achieved. The ability to integrate diverse research capabili-
ties from the two councils and achieve the maximum impact
is ASTAR’s one signiﬁcant value proposition to industry.
V. COLLABORATING WITH INDUSTRY IN R&D
THROUGH INNOVATION PLATFORMS
The concept of collaboration in research extends beyond
the ASTAR RIs to include industry players as well. In line
with the recommendations of the Economic Strategies Com-
mittee’s subcommittee on “Growing Knowledge Capital”2 to
establish Singapore as Asia’s innovation capital—a vibrant
hub for knowledge creation, innovation, and enterprise,
ASTAR is taking the lead to engage and partner industry in
R&D so as to grow innovation capital. Innovation capital
refers to our ability to translate ideas to the marketplace and
create value from our R&D investments. To achieve this, we
are aligning some of our knowledge creation efforts with the
marketplace and put in place innovation platforms that offer
ﬂexible and customized approaches to cater to the needs of
different types of enterprises and foster research collabora-
tions among the different R&D players. These enterprises
include MNCs, globally competitive companies GCCs,
small and medium enterprises SMEs, and high tech start-
ups. Our approach will also capitalize on the advantages of
our environment, in particular that of a “whole of Singapore”
approach, to enable us to integrate our efforts and build
greater collaboration and alignment between the public and
private sector.
One of the innovation platforms we have developed is the
research consortium to foster research collaborations among
different R&D players. An example is the ASTAR Aero-
space Consortium, set up in 2007, which brings together 18
companies from the aerospace industry. The companies in-
clude aerospace industry giants such as Boeing, EADS, Pratt
& Whitley, and Rolls Royce; other MNCs such as BASF,
Sonatest, and IDI Laser Services; local GCCs such as SIA
Engineering Company; and SMEs such as IDI Laser, Sunny
Instruments, and TruMarine. These companies come together
to collaborate with our various SERC RIs in precompetitive
R&D that are valued by the industry. Such a platform will
create new knowledge for use globally as well as enable the
Singapore aerospace industry to grow and move up the in-
dustry value chain—from the current service-oriented activi-
ties in maintenance, repair, and overhaul to higher value-
added R&D such as design and manufacturing. By teaming
up SMEs with MNCs through the Aerospace Consortium, we
are also nurturing a local supply chain and open up business
opportunities for the local enterprises.
The three-dimensional through-silicon via 3D-TSV con-
sortium is another example of research consortia innovation
platform that ASTAR established last year. This consortium
brings MNCs and local research institutes together to re-
search on 3D-TSV, touted to be a key alternative enabling
technology to boost next-generation wafer manufacturing ca-
pability. This will make electronic devices smaller than ever
and give our semiconductor industry a leg-up to get it ready
for the next wave of product miniaturization. Other more
recent examples include Micro-Electro-Mechanical-Systems
MEMS Consortium and the Industrial Consortium on
Nanoimprint ICON.
VI. PARTNERING CLINICIANS IN HOSPITALS FOR
BIOMEDICAL ENGINEERING RESEARCH
By 2008, the BMS landscape in Singapore has evolved
greatly. Besides the biologics and pharmaceutical industries,
the healthcare services and medical technology industries are
also growing. By then, the medical technology industry al-
ready had an output of S$3 billion and employed more than
8000 people in Singapore in 2008. It has also seen early
successes in attracting leading MedTech companies, such as
Hill-Rom and Siemens Medical, to invest in R&D in Sin-
gapore. A total of 30 MedTech companies with manufactur-
ing activities hiring more than 400 researchers, scientists,
and engineers have been set up in Singapore then. The pros-
pect of the medical technology in Singapore looked bright,
given the growing Asian market and the need for companies
to customize their products and services to this market. This
is why ASTAR decided to give this sector a decisive push.
ASTAR has the natural advantage of venturing into
medical research technology. Research in this area is charac-
terized by cross-disciplinary research collaborations among
clinicians, biomedical scientists, and engineers, and it is de-
ﬁned by a constant ﬂow of innovation to develop meaningful
solutions to address complex medical problems. ASTAR,
with the spectrum of capabilities in basic BMS research and
translational and clinical research, and our traditional
strengths in physical sciences and engineering research, plus
the capacity to advance cross council research collaborations,
was in a unique position to give the medical technology in-
dustry an added push to develop it further.
We, therefore, launched the Biomedical Engineering Pro-
gram in 2009 and created opportunities for ASTAR re-
searchers to collaborate with clinicians in hospitals. Under
2Economic Strategies Committee. August 11, 2010. http://www.esc.gov.sg/
attactments/
Subcommittee%20on%20Growing%20Knowledge%20Capital.pdf
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this program, grants are awarded to research projects helmed
collaboratively by research engineers at ASTAR and clini-
cians in local hospitals, and involving researchers from the
universities and hospitals. These projects aim to develop and
provide cost-effective, innovative, and clinically impactful
solutions for healthcare systems. With the active participa-
tion of clinicians who understand the needs of their patients,
these projects will be highly relevant to patients and be able
to meet their needs. The intention is for these innovations to
eventually be developed for the local, regional, and interna-
tional markets.
Two examples of on-going projects are the advanced re-
habilitation therapy for stroke based on brain-computer inter-
face jointly led by Dr. Guan Cuntai from the Institute for
Infocomm Research and Dr. Karen Chua from Tan Tock
Seng Hospital, in collaboration with Dr. Ang Beng Ti from
National Neuroscience Institute. This project makes use of
the novel and award-winning technology of the brain com-
puter interface also developed by Dr. Guan, and improves on
it to achieve a holistic and comprehensive system for ad-
vanced rehabilitation therapy for stroke patients. Another
project is automatic glaucoma diagnosis and its genetic as-
sociation study through medical image informatics AG-
LAIA led by Dr. Jimmy Liu from I2R and Professor Wong
Tien Yin from Singapore Eye Research Institute. When it is
developed, AGLAIA will be the ﬁrst of its kind software
system that will be able to detect and diagnose glaucoma in
the general populace in a cost-effective and efﬁcient manner.
To augment the medical technology research, ASTAR
also designed the ASTAR-Center for Integration of Medi-
cine and Innovative Technology CIMIT program in 2009,
which is an adaptation of the model by the Boston-based
research consortium, CIMIT. Under this program, opportuni-
ties will be created for engineers, clinicians, and BMS scien-
tists in Singapore to work with clinicians in Boston to come
up with engineering solutions that have clinical and market
relevance. This will allow us to leverage on CIMIT’s existing
technologies and best practices which will signiﬁcantly
shorten our own innovation cycles. The collaboration will
result in the codevelopment of intellectual property between
ASTAR, the universities, hospitals, and CIMIT in time to
come. This will accelerate the commercialization of innova-
tive medical technologies and also give rise to high tech
start-ups.
In addition, ASTAR also established the Singapore-
Stanford Biodesign SSB program this year to train teams of
young professionals from diverse backgrounds, from the
medical, engineering, and business disciplines, to develop
innovative medical devices to address Asia’s growing health-
care needs. The SSB will also start innovation classes in
NUS and NTU to equip graduate students with the skills to
participate in the I&E value chain. They will be able to par-
ticipate as innovators, technology transfer professionals,
patent agents, and start-up mentors to lead and carry out
R&D and R&D commercialization activities to achieve eco-
nomic impact.
VII. CONTRIBUTING TO THE SINGAPORE
ACADEMIC SYSTEM
We recognize the need to develop a pipeline of local sci-
entiﬁc talent who will form the core group of researchers in
ASTAR and Singapore. To that end, ASTAR has been pro-
viding plenty of opportunities to young Singaporeans to pur-
sue their passion in science and realize their potential
through our various scholarship and investigatorship pro-
grams.
The scholarships include the national science scholarship
for top young Singaporeans to pursue undergraduate studies
all the way to Ph.D. levels at top overseas universities, and
the ASTAR graduate scholarship which gives top local
graduates from NUS and NTU a chance to do their Ph.D.
training at nine prestigious universities locally and abroad3
through a sandwich Ph.D. program. In addition, ASTAR
also offers Ph.D. graduates from NUS and NTU who are
keen on a life of research the ASTAR international fellow-
ship. This gives them the chance of undertaking a two year
fully funded postdoctoral training at top overseas universities
and private sector laboratories of their choice. Such training
will expand their research experience, deepen their domain
knowledge as well as enable them to establish networks and
linkages with international researchers.
To date, we have exceeded our target of awarding 1000
scholarships to local talent to be trained at the Ph.D. levels
and beyond. Of this number, about 240 of the scholars and
fellows have completed their Ph.D. training and are working
in the various ASTAR research institutes. However, we are
not resting on our laurels and will continue attracting prom-
ising young talent to pursue a career in research.
Attracting and developing promising international
talent
In addition to local scientiﬁc talent, we are also adding
diversity to the research environment by attracting top for-
eign Ph.D. students and postdoctorals from all corners of the
world. They not only add color to the environment in
ASTAR and the local universities, but they also partner us
in contributing toward Singapore’s development as a
knowledge-based and innovative-driven economy. For many
of them, they will also become the future bridges that link
ASTAR to the research communities in their host countries.
Some of the programs we have put in place to bring in top
talent at different levels include the ASTAR Investigator-
ship Program, the Singapore International Graduate Award
and the ASTAR research attachment program.
3the universities include the following: Carnegie Mellon University, Impe-
rial College London, Karolinska Institutet, Nanyang Technological Univer-
sity, National University of Singapore, University of Cambridge, Univer-
sity of Dundee, University of Illinois at Urbana-Champaign, and
University of Oxford.
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VIII. CONCLUSION
The various plans have been put in place to advance R&D
in BMS. These include multidisciplinary and cross council
research, partnering industry for growth through customized
innovation platforms, collaborating with the clinical commu-
nity to advance biomedical engineering research, and attract-
ing and developing local scientiﬁc talents. The plans are
carefully designed and implemented, and are made possible
because of the inherent strengths in the Singapore system to
be able to plan and act long term. They are a record of the
efforts made by ASTAR to innovate relentlessly with the
times to help Singapore sustain its competitive advantage.
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